BIXTOTC

BIOXYTRAN, INC

Healthcare·Neurology·Phase 2·Needham, MA, United States

NeurologyInfectious DiseaseRespiratory

BIOXYTRAN, INC (BIXT): 6 pipeline candidates. Updated within the last hour.

8.6/10

BioSniper Score

3-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health10.0

0% dilution

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth9.8

6 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for BIOXYTRAN, INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$3.5M

Cash

—

Quarterly Burn

$239K

Runway

—

Revenue

—

Pipeline (6 candidates)

Drug	Phase	Indication
BXT-25	Preclinical	ischemic stroke
ProLectin-A	Preclinical	ARDS as a result of Covid-19
ProLectin-F	Preclinical	lung-fibrosis as a result of the use of ventilators used for...
ProLectin-I	Preclinical	severe cases of Covid-19, lung-fibrosis
ProLectin-M	Phase 2	mild to moderate COVID-19
ProLectin-Rx	—	Treatment of viral diseases in humans, notably SARS-CoV-2 (C...

·CEO: Dr. David Platt Ph.D.

Frequently asked questions

How many drug candidates are in BIOXYTRAN, INC's pipeline?

BIOXYTRAN, INC (BIXT) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is BIOXYTRAN, INC's lead drug candidate?

BIOXYTRAN, INC's most advanced tracked candidate is BXT-25 (Preclinical) for ischemic stroke.

What is BIOXYTRAN, INC's market capitalization?

BIOXYTRAN, INC's market capitalization is approximately $3.5M.

Who is the CEO of BIOXYTRAN, INC?

Dr. David Platt Ph.D. is the chief executive officer of BIOXYTRAN, INC (BIXT).

Get the full picture on BIOXYTRAN, INC

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free Analysis Browse Calendar